Trial Profile
A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2015
Price :
$35
*
At a glance
- Drugs Bifeprunox (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Abbott Laboratories
- 30 Sep 2006 New trial record.